A comprehensive view of Combination Therapy. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer reports combination COVID-19 booster based on original vaccine with omicron-specific protection and omicron-specific booster vaccine both increase omicron-fighting antibodies in tests; omicron-specific booster had strongest response against omicron
Published: June 28, 2022 by Associated Press
US health authorities debate whether to use modified vaccines for fall COVID-19 booster shots, with bivalent combination shots of original vaccine plus omicron protection top candidates; about 50% in US have never received first dose of vaccine
Published: June 28, 2022 by Associated Press
Pfizer partners with MorphoSys, Incyte to evaluate combined therapy to treat diffuse large B-cell lymphoma, a type of blood cancer; drugs include Pfizer’s experimental TTI-622, Morphosys and Incyte’s Monjuvi tafasitamab-cxix, Revlimid lenalidomide
Published: June 15, 2022 by SeeNews Pharmaceuticals
FDA approves Amgen’s injectable Riabni rituximab-arrx, a biosimilar of Rituxan rituximab, to treat moderate to severe rheumatoid arthritis in adults; drug is used in combination with methotrexate
Published: June 07, 2022 by PR Newswire
FDA approves Bristol Myers’ Opdivo nivolumab injectable used with chemotherapy and Opdivo plus Yervoy ipilimumab to treat advanced, metastatic esophageal squamous cell carcinoma; 20,640 new cases of esophageal cancer are diagnosed in US annually
Published: June 01, 2022 by PharmaBiz

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count